Healthcare entity
All 1 tracked stories fall under one category: market-trends. BioMarin Pharmaceutical is most often covered alongside Myriad Genetics, which appears in 1 of these 1 story. Each story carries 4 original sources on average, compared with 6 for the broader beat in this window.
Last mentioned: Feb 20, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: market-trends. BioMarin Pharmaceutical is most often covered alongside Myriad Genetics, which appears in 1 of these 1 story. Each story carries 4 original sources on average, compared with 6 for the broader beat in this window. Their average consequence score of 5 runs below the beat's 5.8 for that window. We currently track 1 Healthcare story that mention BioMarin Pharmaceutical, all published on February 20, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering BioMarin Pharmaceutical. Shared-story counts are live from our verified record — not editorial picks.
A critical wave of fourth-quarter 2025 earnings previews highlights a sector-wide focus on clinical execution and commercial scaling for mid-to-large cap biotech players. Summit Therapeutics' ivonescimab progress and BioMarin's Voxzogo expansion remain the primary catalysts for investor sentiment as the industry navigates a disciplined capital environment.
Source: Seeking Alpha · Seeking Alpha
BioMarin Pharmaceutical is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
